The R&D and manufacturing site in the city of Wuxi was put into operation

Wuhan site was put into operation, and it became the key of WuXi AppTec's strategic network in central and western China

WuXi AppTec opened a new facility in Philadelphia, Pennsylvania, strengthening R&D and production services of CAR-T therapies and other immunotherapies

WuXi AppTec Laboratory Testing Division expanded with acquisition of XenoBiotic Laboratories in Plainsboro, New Jersey, bolstering LTD's bioanalytical and DMPK/ADME services for U.S. customers

WuXi AppTec acquired Crelux, enhancing WuXi AppTec's structure-based drug discovery capabilities in Europe

STA began operations at a new, fully integrated R&D and cGMP manufacturing site in Changzhou

WuXi AppTec acquired HD Biosciences in San Diego, California, strengthening U.S. biology R&D capacity and capability

WuXi AppTec acquired ResearchPoint Global in Austin, Texas, expanding U.S. clinical research capabilities

WuXi AppTec built up its Life Science Industry Park in Chengdu

WuXi AppTec announced listing of Initial Public Offering of Common Stock on the Shanghai Stock Exchange (stock code: 603259.SH)

WuXi AppTec listed H shares on the Hong Kong Stock Exchange (stock code: 2359.HK)

The first WuXi Healthcare Forum held in Shanghai

WuXi AppTec acquired Pharmapace in San Diego, California, to enhance biometrics services for clinical development

WuXi STA oligonucleotide large-scale manufacturing facility was put into operation

WuXi AppTec hosted a series of online COVID-19 forums to strengthen the collaboration across the global healthcare industry

The Chengdu site of WuXi AppTec was put into operation

WuXi Advanced Therapies expanded Philadelphia campus with new state-of-the-art testing laboratory

WuXi STA purchased Bristol Myers Squibb manufacturing facility in Couvet, Switzerland

WuXi AppTec acquired OXGENE to further strengthen Cell and Gene Therapy service offerings for global customers

WuXi STA announced to build new pharmaceutical manufacturing campus in Middletown, Delaware

WuXi ATU opened new facility in Philadelphia, tripling testing capacity to support global customers

WuXi STA opened new large-scale oligonucleotide and peptide manufacturing facility

WuXi AppTec planned to build a new site in Singapore, better serving global partners and advancing healthcare innovation